

Applicants: Jeffrey Sterling et al.
Serial No.: 10/718,879
Filed: November 20, 2003
Exhibit A



Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
67694-A/JPW/GJG/MMLSerial No.
10/718,879INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicants: Jeffrey Sterling, et al.

Filing Date
November 20, 2003

Group

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
SY	2 8 2 2 3 5 9	2/4/58	Straley et al.;			
SY	4 5 3 5 0 8 8	8/13/85	Makisumi et al.;			
SY	4 8 2 6 8 6 0	5/2/89	Johnson et al.;			
SY	4 9 1 8 0 9 0	4/17/90	Johnson et al.;			
SY	4 9 7 1 9 8 3	11/20/90	Johnson et al.;			
SY	5 4 5 3 4 4 6	9/26/95	Youdim et al.;			
SY	5 7 4 4 5 0 0	4/28/98	Youdim et al.;			

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation	
					Yes	No
SW 0 6 6 7 6 9 1	9/15/88	Switzerland,				
SY EP 0 2 8 2 9 7 1	9/21/88	EPO;				
SY WO 0 0 7 4 6 7 6	12/14/00	PCT;				
SY WO 0 1 9 5 9 0 7	12/20/01	PCT;				
SY WO 0 3 07 2 0 5 5	9/4/03	PCT;				
SY WO 20 04 04 7 7 5 6	9/4/03	PCT;				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SY	Barnett C. J. and J. C. Smirz. (1974) <u>Organic. Prep. Proc. Int.</u> , 6(4):179-82;
SY	Ben Simon et al. (1994) "A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis." <u>New Engl. J. Med.</u> , 330:585-91;
SY	Berge et al. (1977) "Pharmaceutical Salts." <u>J. Pharm. Sci.</u> , 66:1-19
SY	Domino, E.F. et al. (1952) "Pharmacological properties of benzazoles. I. Relationship between structure and paralyzing action." <u>J. Pharmacol. Exp. Ther.</u> , 105: 486-97;
SY	Dreikorn, B.A. and Unger, P. (1989) <u>J. Heterocyclic Chem.</u> ; 26:1735-7
SY	Haley T.J and McCormick W.G. (1957) "Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse." <u>Brit. J. Pharmacol.</u> , 12:12-5;
SY	Jimonet, P. et al. (1999) "Riluzole series. Synthesis and in vivo "antiglutamate" activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines." <u>J. Med. Chem.</u> , 42:2828-3;
SY	Kalkers, N.F. et al. (2002) "The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study." <u>Mult. Scler.</u> , 8:532-3;
SY	Katritzky, K.R. et al. (1987) "N-monomethylation of primary amines via intermediate benzothiazol-2(3H)-imines." <u>J. Chem. Soc., Perkin Trans. I</u> , 2539-41;
SY	<u>The MERCK Index</u> , 12 th Edition, p.1416 (1996) MERCK & Co. Inc.;
SY	<u>The MERCK Manual</u> , 17th Edition, Section 14, Chapter 180 (1999) MERCK & Co. Inc.
SY	Naai, M. et al. (2002) "Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, and neuroprotection by propargylamines." <u>J. Neural Transmission</u> , 109:607-721;
SY	Sasaki et al., (1998) "Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases." <u>Am. J. Pathol.</u> , 153:1149-55;
SY	Tisch, R and McDevitt, HO. (1994) "Antigen-Specific Immunotherapy: Is It a Real Possibility to Combat T-Cell-Mediated Autoimmunity?" <u>Proc. Natl. Acad. Sci. U.S.A.</u> , 91:437-8; and
SY	Youdim, M.B.H. and Weinstock M. (2001) "Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoinidan-5-YL)-ethyl methyl carbamate]." <u>Cell. Mol. Neurobiol.</u> , 21(6): 555-73.

EXAMINER /Shawquia Young/ DATE CONSIDERED 08/30/2006

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Jeffrey Sterling et al.
Serial No.: 10/718,879
Filed: November 20, 2003
Exhibit A